Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: Rational design of dosing strategies

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 485-491

  Taylor, Ronald P ^a   Lindorfer, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD20 ANTIGEN;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG MECHANISM; HUMAN; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR VOLUME; ANIMAL; IMMUNOLOGY; NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS;

EID: 84907435331     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.092684     Document Type: Review

References (80)

1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, and Beers SA et al. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosomemediated cell death in B-cell malignancies. Blood 117:4519-4529.
2. Atkinson JP and Frank MM (1974) Complement-independent clearance of IgGsensitized erythrocytes: inhibition by cortisone. Blood 44:629-637.
3. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, and Wiestner A (2010) Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 95:329-332.
4. Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, and Zent CS (2014) Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complementdependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol 192: 1620-1629.
5. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, and Flinn IW (2007) Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 13:2392-2399.
6. Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, and Shen D (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995-1001.
7. Beum PV, Kennedy AD, and Taylor RP (2004) Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289:97-109.
8. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, and Taylor RP (2006) The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176:2600-2609.
9. Beum PV, Lindorfer MA, and Taylor RP (2008a) Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 181:2916-2924.
10. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, and Taylor RP (2008b) Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181: 8120-8132.
11. Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JGJ, and Taylor RP (2011) Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 187:3438-3447.
12. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJM, Parren PWHI, Wiestner A, and Taylor RP (2012) Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 188:3532-3541.
13. Bhat R and Watzl C (2007) Serial killing of tumor cells by human natural killer cells -enhancement by therapeutic antibodies. PLoS ONE 2:e326.
14. Bianchini G and Gianni L (2014) The immune system and response to HER2- targeted treatment in breast cancer. Lancet Oncol 15:e58-e68.
15. Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, and Golay J (2013) Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 190:231-239.
16. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, and Golay J (2011) Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 186:3762-3769.
17. Boross P, Jansen JH, Pastula A, van der Poel CE, and Leusen JHW (2012) Both activating and inhibitory Fc g receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol Lett 143:44-52.
18. Boross P, Jansen JHM, de Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JGJ, and Parren PWHI et al. (2011) The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 96:1822-1830.
19. Boross P and Leusen JHW (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2:676-690.
20. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, and Tassone P et al. (2012) Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 35:440-447.
21. Bowles JA and Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304:88-99.
22. Boyer TD (2003) Zakim and Boyer's Hepatology: A Textbook of Liver Disease, Saunders, Philadelphia.
23. Bulliard Y, Jolicoeur R,WindmanM, Rue SM, Ettenberg S, Knee DA,Wilson NS, Dranoff G, and Brogdon JL (2013) Activating Fc g receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J ExpMed 210:1685-1693.
24. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, and Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
25. Cheson BD (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28:3525-3530.
26. Cheson BD and Leonard JP (2008) Monoclonal antibody therapy for B-cell non- Hodgkin's lymphoma. N Engl J Med 359:613-626.
27. Clynes RA, Towers TL, Presta LG, and Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446.
28. Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, Frederiksen H, van Oers MHJ, Wooldridge J, and Kloczko J et al. (2010) Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol 150:58-71.
29. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, and Hudrisier D (2010) The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol 184:1897-1908.
30. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, and Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 18:3135-3143.
31. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, and Flinn I et al. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997-1007.
32. Glennie MJ, French RR, Cragg MS, and Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823-3837.
33. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy M-S, and Illmer T et al. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370: 1101-1110.
34. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, and Introna M (2013a) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:3482-3491.
35. Golay J and Introna M (2012) Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 526:146-153.
36. Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, and Zaja F et al. (2013b) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5:826-837.
37. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, and Chen Y et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-826.
38. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, and von Grünhagen U et al.; International Group of Investigators; ; German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174.
39. Jain RK and Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022-7032.
40. Joly E and Hudrisier D (2003) What is trogocytosis and what is its purpose? Nat Immunol 4:815.
41. Jones JD, Hamilton BJ, and Rigby WFC (2012) Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum 64:3111-3118.
42. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, and Taylor RP (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280-3288.
43. Kim JM and Ashkenazi A (2013) Fcg receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med 210:1647-1651.
44. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, and Coutre S et al. (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117: 2423-2432.
45. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, and Carlson RW et al. (2012) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 122:1066-1075.
46. Laurent C, de Paiva GR, Ysebaert L, Laurent G, March M, Delsol G, and Brousset P (2007) Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphoma. Am J Clin Pathol 128:974-980.
47. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, and Taylor RP (2007) Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 179: 4263-4271.
48. Lindorfer MA, Kohl J, and Taylor RP (2014) Interactions between the complement system and Fcg receptors, in Antibody Fc: Linking Adaptive and Innate Immunity (Ackerman ME and Nimmerjahn F eds) pp 49-74, Elsevier, Philadelphia.
49. Lindorfer MA, Wiestner A, Zent CS, and Taylor RP (2012) Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? OncoImmunology 1:959-961.
50. Mahalingam D and Curiel TJ (2013) Antibodies as cancer immunotherapy, in Cancer Immunotherapy: Paradigms, Practice and Promise (Curiel TJ ed) pp 335-376, Springer, New York.
51. Masuda S, Iwasaki S, Tomaru U, Baba T, Katsumata K, and Ishizu A (2013) Possible implication of Fc g receptor-mediated trogocytosis in susceptibility to systemic autoimmune disease. Clin Dev Immunol 2013:345745.
52. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, and Cabanillas F et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833.
53. Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, and Bousso P (2013) The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 123:5098-5103.
54. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJS, Horne H, and Teoh N et al. (2009) Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 27:3346-3353.
55. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, and van Puijenbroek E et al. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-4402.
56. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, and Bisagni G et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796.
57. Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, and Goldenberg DM (2011) Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica 96:567-573.
58. Pedersen AE, Jungersen MB, and Pedersen CD (2011) Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology 133:239-245.
59. Peipp M, van de Winkel JGJ, and Valerius T (2011) Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 24: 217-229.
60. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, and Chang CH (2013) Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood 122:3020-3029.
61. Schreiber AD and Frank MM (1972) Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest 51:575-582.
62. Scott AM, Wolchok JD, and Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278-287.
63. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, and Wolchok JD et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695-1710.
64. Sliwkowski MX and Mellman I (2013) Antibody therapeutics in cancer. Science 341: 1192-1198.
65. Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, and Keating MJ (2008) Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 141:36-40.
66. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, and Strome SE (2009) FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 58:997-1006.
67. Taylor RP (2013) Gnawing at Metchnikoff's paradigm. Blood 122:2922-2924.
68. Taylor RP and Lindorfer MA (2014) The role of complement in mAb-based therapies of cancer. Methods 65:18-27.
69. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, and Dechant M et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-1800.
70. Teng YKO, Levarht EWN, Hashemi M, Bajema IM, Toes REM, Huizinga TWJ, and van Laar JM (2007) Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56:3909-3918.
71. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, and Ménard S et al. (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991-11999.
72. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, and Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118:3347-3349.
73. Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115-123.
74. Weng WK and Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947.
75. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, and Taylor RP (2006) Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177:7435-7443.
76. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Li Y, Pitti R, Totpal K, and Yee S et al. (2011) An Fcg receptor-dependent mechanism drives antibodymediated target-receptor signaling in cancer cells. Cancer Cell 19:101-113.
77. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, and Schichman SA (2004) Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 28:495-507.
78. Zent CS, Taylor RP, Lindorfer MA, Beum PV, Laplant B, Wu W, Call TG, Bowen DA, Conte MJ, and Frederick LA et al. (2014) Chemoimmunotherapy for relapsed/ refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol 89:757-765.
79. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, and Sherrod AE et al. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718.
80. Zigler M, Shir A, and Levitzki A (2013) Targeted cancer immunotherapy. Curr Opin Pharmacol 13:504-510.